
When the American Academy of Pediatrics released revised recommendations for the management of hypercholesterolemia in children this year, a media firestorm erupted over the inclusion of statins as potential first-line pharmacologic agents. But the epidemic of childhood obesity has forced pediatricians to balance the unknown risks associated with pharmacologic therapy in children against the risk that failure to treat could lead to heart attacks and other complications in young adulthood, according to a Perspective article published in the Sept. 25 issue of the New England Journal of Medicine.